Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1. Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis. A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR = 1.40, 95% CI: 1.17 ~ 1.68; P<0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR = 1.35, 95%CI: 0.87–2.10; P = 0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P = 0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results. Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.

中文翻译：

---

TSP-1作为各种癌症的预后标志物的作用：系统评价和荟萃分析。

已发表的研究提出了关于血小板反应蛋白-1（TSP-1）表达对各种癌症预后的影响的相互矛盾的数据。我们进行了这项荟萃分析，以说明TSP-1的初步预测价值。纳入了总共2379名患者的24项研究。使用PubMed，Cochrane图书馆，Web of Science，Embase进行了全面的文献检索，还对相关书目进行了人工检索。最初确定了95％置信区间（CIs）对患者生存和疾病复发的合并危险比（HRs），以探索TSP-1表达与患者预后之间的关系。这项荟萃分析共纳入24项合格研究。我们的结果表明，高水平的TSP-1与不良的总体生存率（OS）显着相关（HR = 1.40，95％CI：1.17〜1.68; P ＜0.001）。然而，高TSP-1表达预测对无进展生存期（PFS）/无转移生存期（MFS）的影响不显着（HR = 1.35，95％CI：0.87–2.10； P = 0.176）和无病生存期（ DFS）/无复发生存期（RFS）（HR = 1.40，95％CI：0.77–2.53； P = 0.271）。此外，我们进行了亚组分析，结果表明高TSP-1表达可预测乳腺癌和妇科癌症的不良预后。此外，关于PFS / MFS和DFS / RFS的研究相对较少，这是一个局限。通过Kaplan-Meier曲线提取的数据可能不准确。此外，本文仅包含英文文章，这可能会导致结果出现偏差。我们的研究结果表明，高TSP-1表达可能是癌症预后不良的有前途的生物标志物，